PRESS RELEASE published on 07/09/2024 at 20:45, 2 years 2 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its 2023 annual results, financial highlights, and financing outlook. Annual General Meeting scheduled for September 13, 2024 Annual General Meeting Financial Highlights 2023 Annual Results ACTICOR BIOTECH Financing Outlook
PRESS RELEASE published on 07/09/2024 at 20:45, 2 years 2 months ago Informations privilégiées / Communiqué sur comptes, résultats Acticor Biotech publie ses résultats financiers annuels pour 2023, avec une perte nette de 18,640 K€. La trésorerie s'élève à 3,9 M€. L'AG se tiendra le 13 septembre 2024 Résultats Financiers Assemblée Générale Trésorerie Perte Nette ACTICOR BIOTECH
BRIEF published on 05/15/2024 at 11:20, 2 years 3 months ago Résultats de l'étude ACTISAVE et perspectives futures d'ACTICOR BIOTECH ACTICOR BIOTECH Étude ACTISAVE Traitement AVC Glenzocimab ESOC 2024
BRIEF published on 05/15/2024 at 11:20, 2 years 3 months ago Results of the ACTISAVE study and future perspectives of ACTICOR BIOTECH Stroke Treatment ACTICOR BIOTECH Glenzocimab ESOC 2024 ACTISAVE Study
PRESS RELEASE published on 05/15/2024 at 11:15, 2 years 3 months ago Informations privilégiées / Autres communiqués ACTICOR BIOTECH présente les résultats de l'étude ACTISAVE sur le traitement de l'AVC ischémique lors de l'ESOC 2024. Perspectives prometteuses pour le glenzocimab malgré l'absence d'efficacité globale ACTICOR BIOTECH Glenzocimab ESOC 2024 AVC Ischémique ACTISAVE
PRESS RELEASE published on 05/15/2024 at 11:15, 2 years 3 months ago Inside Information / Other news releases ACTICOR BIOTECH presents main results of phase 2/3 ACTISAVE study on stroke treatment at ESOC 2024, targeting specific subgroups for potential benefits Stroke Treatment ACTICOR BIOTECH ESOC 2024 ACTISAVE Study Patient Subgroups
Published on 09/12/2026 at 02:35, 11 hours 1 minute ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 36 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 31 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 11 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 36 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 5 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 21 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 25 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 51 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 20 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
